A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Clinical trial NCT03075644 · COMPLETED
Trial details
- NCT number
- NCT03075644
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-03
- Primary completion
- 2018-10-04
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.